Records containing: Waldenstrom Macroglobulinemia

This is the wording recorded or indexed by the source. An agency index term is not necessarily an authorised indication. Co-listed drug names are not linked to this term as a treatment relationship.

All FDA submission records EMA medicine records ClinicalTrials.gov record updates ClinicalTrials.gov records with results posted

CLINICAL_TRIALS study record update · 2025-04-04
Efficacy and Safety of Carfilzomib in Combination With Ibrutinib vs Ibrutinib Alone in Waldenström's Macroglobulinemia (CZAR-1)
CLINICAL_TRIALS study record update · 2025-02-24
A Phase 1 Clinical Trial to Study the Safety, Pharmacokinetics, and Efficacy of BP1002 (L-Bcl-2) Antisense Oligonucleotide in Patients With Advanced Lymphoid Malignancies
CLINICAL_TRIALS study record update · 2024-12-18
Expanded Access Program for Pirtobrutinib for Previously Treated B-Cell Cancers
CLINICAL_TRIALS study record update · 2024-12-18
The Registry of Oncology Outcomes Associated With Testing and Treatment (ROOT)
CLINICAL_TRIALS study record update · 2024-11-07
A Phase II Trial to Investigate the Safety and Efficacy of Rituximab and Pembrolizumab in Relapsed/Refractory Waldenström's Macroglobulinaemia
Organize your saved records without ads with Plus.
CLINICAL_TRIALS study record update · 2024-10-03
B-Cell Hematologic Malignancy Vaccination Registry
CLINICAL_TRIALS study record update · 2024-09-19
1630GCC: A Pilot Study of Zydelig in Patients With B-cell Malignancies as Post-Autologous Transplant Remission Maintenance
CLINICAL_TRIALS study record update · 2024-08-28
Phase II Clinical Study of Zanubrutinib Combined With Bendamustine and Rituximab (ZBR) for Time-limited Treatment of Waldenstrom Macroglobulinemia
CLINICAL_TRIALS study record update · 2024-08-20
A Phase 1, Open-label, Dose Escalating Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Clinical Activity of the Combination of CLBR001 and SWI019 in Patients With Relapsed/Refractory B-cell Malignancies
CLINICAL_TRIALS study record update · 2024-05-22
OCT and OCTA Deep Learning in Waldenström's Macroglobulinemia Patients
CLINICAL_TRIALS study record update · 2024-05-10
Randomised Phase II/III Study of Rituximab and Ibrutinib (RI) Versus Dexamethasone, Rituximab and Cyclophosphamide (DRC) as Initial Therapy for Waldenström's Macroglobulinaemia
CLINICAL_TRIALS study record update · 2024-04-23
Phase II Study on the Combination of Ibrutinib and Venetoclax in Treatment naïve Patients With Waldenström Macroglobulinemia
CLINICAL_TRIALS study record update · 2024-04-02
A Phase II Trial of Haploidentical Allogeneic Stem Cell Transplantation Utilizing Mobilized Peripheral Blood Stem Cells
CLINICAL_TRIALS study record update · 2024-03-21
Dasatinib in Patients With Waldenström Macroglobulinemia (WM) Progressing on Ibrutinib
CLINICAL_TRIALS study record update · 2024-01-12
A Phase 1 Dose-Escalation and Cohort-Expansion Study of VLS-101 in Subjects With Hematological Malignancies (waveLINE-001)
CLINICAL_TRIALS study record update · 2023-11-22
A Phase I Study of CD8 Memory T-Cell Donor Lymphocyte Infusion for Relapse of Hematolymphoid Malignancies Following Matched Related Donor Allogeneic Hematopoietic Cell Transplantation
CLINICAL_TRIALS study record update · 2023-10-23
A Phase II Study of Daratumumab Plus Ibrutinib in Patients With Waldenstrӧm's Macroglobulinemia
CLINICAL_TRIALS study record update · 2023-10-18
A Pilot Trial Examining Myeloid-Derived Suppressor Cells and Checkpoint Immune Regulators' Expression in Allogeneic Stem Cell Transplant Recipients Using Myeloablative Busulfan and Fludarabine
CLINICAL_TRIALS study record update · 2023-08-29
An Open Label Non-randomized Phase II Study Exploring "Chemo-free " Treatment Association With Idelalisib + Obinutuzumab in Patient With Relapsed/Refractory Waldenstrom's Macroglobulinemia
CLINICAL_TRIALS study record update · 2023-06-23
A Phase 2 Study to Assess the Efficacy and Safety of TGR-1202 (Umbralisib) Monotherapy in Patients With Non-Follicular Indolent Non-Hodgkin's Lymphoma
CLINICAL_TRIALS study record update · 2023-03-21
A Phase II Study of Anti-PD-1 Antibody (MK-3475) in Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL) and Other Low Grade B Cell Non-Hodgkin Lymphoma (NHL)
CLINICAL_TRIALS study record update · 2023-02-21
A Multicenter, Open-label, Phase 1 Study Evaluating the Safety and Tolerability of HMPL-760 in Patients With Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) or Other Non-Hodgkin Lymphoma (NHL)
CLINICAL_TRIALS study record update · 2023-02-09
BrUOG 326: A Phase I Dose-Escalation Study of Vincristine Sulfate Liposome Injection (Marqibo®) in Combination With Bendamustine and Rituximab (BRiM) in Indolent Non-Hodgkin Lymphoma
CLINICAL_TRIALS study record update · 2022-12-01
Phase 2 Study of Bruton's Tyrosine Kinase (BTK) Inhibitor, Ibrutinib (PCI-32765) in Combination With Rituximab, in Japanese Patients With Waldenstrom's Macroglobulinemia (WM)
CLINICAL_TRIALS study record update · 2022-11-23
Nonmyeloablative Allogeneic Hematopoietic Stem Cell Transplantation Using Antithymocyte Globulin With Either Melphalan and Cladribine or Total Lymphoid Irradiation